90578 Search Results


hs 90 578t  (ATCC)
90
ATCC hs 90 578t
Hs 90 578t, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hs 90 578t/product/ATCC
Average 90 stars, based on 1 article reviews
hs 90 578t - by Bioz Stars, 2025-03
90/100 stars
  Buy from Supplier
ccnb2 shrna plasmids  (Addgene inc)
93
Addgene inc ccnb2 shrna plasmids
Relationships of <t> CCNB2 </t> and clinicopathological characteristics in 114 patients with triple-negative breast cancer (TNBC).
Ccnb2 Shrna Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccnb2 shrna plasmids/product/Addgene inc
Average 93 stars, based on 1 article reviews
ccnb2 shrna plasmids - by Bioz Stars, 2025-03
93/100 stars
  Buy from Supplier

Image Search Results


Relationships of CCNB2 and clinicopathological characteristics in 114 patients with triple-negative breast cancer (TNBC).

Journal: Disease Markers

Article Title: Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

doi: 10.1155/2021/5511041

Figure Lengend Snippet: Relationships of CCNB2 and clinicopathological characteristics in 114 patients with triple-negative breast cancer (TNBC).

Article Snippet: CCNB2 shRNA plasmids were bought from Addgene.

Techniques: Expressing

The CCNB2 mRNA level was upregulated in TNBC tissues and correlated with the prognosis of TNBC patients. (a) CCNB2 mRNA level in 1085 TNBC tissues was significantly higher than that in 291 normal tissues according to TCGA database. (b) CCNB2 expression level was associated with the disease-free survival rates of two groups of TNBC patients ( n = 803 and n = 963, respectively). Results are presented as mean ± SD, ∗∗ p < 0.01.

Journal: Disease Markers

Article Title: Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

doi: 10.1155/2021/5511041

Figure Lengend Snippet: The CCNB2 mRNA level was upregulated in TNBC tissues and correlated with the prognosis of TNBC patients. (a) CCNB2 mRNA level in 1085 TNBC tissues was significantly higher than that in 291 normal tissues according to TCGA database. (b) CCNB2 expression level was associated with the disease-free survival rates of two groups of TNBC patients ( n = 803 and n = 963, respectively). Results are presented as mean ± SD, ∗∗ p < 0.01.

Article Snippet: CCNB2 shRNA plasmids were bought from Addgene.

Techniques: Expressing

CCNB2 expression was enhanced in human TNBC tissues. (a) Immunohistochemical (IHC) assays were performed, and the CCNB2 expression levels in human TNBC tissues were shown (100x and 200x magnification, respectively). (b) IHC assays confirmed the relative low expression of CCNB2 in the corresponding adjacent tissues (100x and 200x magnification, respectively); scale bar indicates 100 μ m.

Journal: Disease Markers

Article Title: Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

doi: 10.1155/2021/5511041

Figure Lengend Snippet: CCNB2 expression was enhanced in human TNBC tissues. (a) Immunohistochemical (IHC) assays were performed, and the CCNB2 expression levels in human TNBC tissues were shown (100x and 200x magnification, respectively). (b) IHC assays confirmed the relative low expression of CCNB2 in the corresponding adjacent tissues (100x and 200x magnification, respectively); scale bar indicates 100 μ m.

Article Snippet: CCNB2 shRNA plasmids were bought from Addgene.

Techniques: Expressing, Immunohistochemical staining

CCNB2 expression was decreased in both MDA-MB-231 and HCC-1937 cells after the transfection of its shRNA plasmids. (a) Quantitative PCR assays exhibited the decreased mRNA levels of CCNB2 after the transfection of its shRNA plasmids in MDA-MB-231 and HCC-1937 cells, respectively. (b) Immunoblot assays showed the decrease of CCNB2 expression after the transfection of CCNB2 shRNA plasmids in both MDA-MB-231 and HCC-1937 cells. Results are presented as mean ± SD, ∗∗ p < 0.01.

Journal: Disease Markers

Article Title: Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

doi: 10.1155/2021/5511041

Figure Lengend Snippet: CCNB2 expression was decreased in both MDA-MB-231 and HCC-1937 cells after the transfection of its shRNA plasmids. (a) Quantitative PCR assays exhibited the decreased mRNA levels of CCNB2 after the transfection of its shRNA plasmids in MDA-MB-231 and HCC-1937 cells, respectively. (b) Immunoblot assays showed the decrease of CCNB2 expression after the transfection of CCNB2 shRNA plasmids in both MDA-MB-231 and HCC-1937 cells. Results are presented as mean ± SD, ∗∗ p < 0.01.

Article Snippet: CCNB2 shRNA plasmids were bought from Addgene.

Techniques: Expressing, Transfection, shRNA, Real-time Polymerase Chain Reaction, Western Blot

CCNB2 ablation suppressed the proliferation of TNBC cells in vitro . (a) Colony formation assays were performed by the use of MDA-MB-231 and HCC-1937 cells transfected with control or CCNB2 shRNA plasmids, and the number of colony in each group was counted. (b) MTT assay results showed the decrease OD value at 570 nm wavelength following CCNB2 depletion. (c) Ki67 expression levels in MDA-MB-231 cells and HCC-137 cells upon the indicated treatment. (d) PCNA expression levels in MDA-MB-231 cells and HCC-1937 cells upon the indicated treatment. Results are presented as mean ± SD, ∗ p < 0.05 and ∗∗ p < 0.01.

Journal: Disease Markers

Article Title: Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

doi: 10.1155/2021/5511041

Figure Lengend Snippet: CCNB2 ablation suppressed the proliferation of TNBC cells in vitro . (a) Colony formation assays were performed by the use of MDA-MB-231 and HCC-1937 cells transfected with control or CCNB2 shRNA plasmids, and the number of colony in each group was counted. (b) MTT assay results showed the decrease OD value at 570 nm wavelength following CCNB2 depletion. (c) Ki67 expression levels in MDA-MB-231 cells and HCC-137 cells upon the indicated treatment. (d) PCNA expression levels in MDA-MB-231 cells and HCC-1937 cells upon the indicated treatment. Results are presented as mean ± SD, ∗ p < 0.05 and ∗∗ p < 0.01.

Article Snippet: CCNB2 shRNA plasmids were bought from Addgene.

Techniques: In Vitro, Transfection, shRNA, MTT Assay, Expressing

CCNB2 promotes tumor growth of TNBC cells in mice. (a) MDA-MB-231 cells infected with control or CCNB2 shRNA plasmids were subcutaneously implanted into nude mice. After 14 days, tumors began formation, and the volume of tumor in each group was measured every 3 days. After 29 days, all tumors were isolated, and the growth curves were shown. (b) Immunoblot assays showed the expression levels of CCNB2 in control or CCNB2 depletion tumors from mice. Results are presented as mean ± SD, ∗ p < 0.05 and ∗∗ p < 0.01. Scale bar indicates 5 mm.

Journal: Disease Markers

Article Title: Cyclin B2 (CCNB2) Stimulates the Proliferation of Triple-Negative Breast Cancer (TNBC) Cells In Vitro and In Vivo

doi: 10.1155/2021/5511041

Figure Lengend Snippet: CCNB2 promotes tumor growth of TNBC cells in mice. (a) MDA-MB-231 cells infected with control or CCNB2 shRNA plasmids were subcutaneously implanted into nude mice. After 14 days, tumors began formation, and the volume of tumor in each group was measured every 3 days. After 29 days, all tumors were isolated, and the growth curves were shown. (b) Immunoblot assays showed the expression levels of CCNB2 in control or CCNB2 depletion tumors from mice. Results are presented as mean ± SD, ∗ p < 0.05 and ∗∗ p < 0.01. Scale bar indicates 5 mm.

Article Snippet: CCNB2 shRNA plasmids were bought from Addgene.

Techniques: Infection, shRNA, Isolation, Western Blot, Expressing